Erin S. Baker
University of North Carolina at Chapel Hill, USA

Erin S. Baker is an Associate Professor at the University of North Carolina at Chapel Hill. To date, she has published over 190 peer-reviewed papers utilizing different analytical chemistry techniques to study both environmental and biological systems. Erin is extremely proud of helping grow the Females in Mass Spectrometry (FEMS + ) group, where she was the Events Committee Chair from 2019-2022 and hosted 35 virtual and 2 in-person events. She is currently serving as the Vice President of Education for the International Lipidomics Society, a mentor for FEMS + , and an Associate Editor for the Journal of the American Society for Mass Spectrometry. Erin has received seven US patents, two R&D 100 Awards, been named to the 2019, 2021, 2023, and 2024 Analytical Scientist Top 100 Power Lists, and was a recipient of the 2016 ACS Rising Star Award for Top Midcareer Women Chemists,2022 ASMS Biemann Medal, and 2022 IMSF Curt Brunnée Award. Currently, her research group utilizes advanced separations and novel software capabilities to examine how chemical exposure affects human health.

Clary Clish
Broad Institute of MIT and Harvard, USA

Clary Clish is Senior Director of the Metabolomics Platform and an Institute Scientist at the Broad Institute of MIT and Harvard. His research is highly collaborative and broadly aims to advance our understanding of the role of metabolism in normal physiology and disease. Current projects range in scope from dissecting metabolic dependencies in cancer to identification of early derangements of metabolism that precede disease, or clinical symptoms of disease, in human cohorts.

Prior to joining the Broad Institute, Clish held senior and executive management positions in the biotechnology industry from 2001-2008, including Vice President of Discovery at Gene Logic Inc. and Director of Metabolite Biochemistry at Beyond Genomics Inc. From 1997-2001, Clish was a postdoctoral fellow and instructor in the laboratory of Dr. Charles Serhan at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham & Women’s Hospital and Harvard Medical School. In the Serhan laboratory, his work focused on understanding the roles of lipidmediators in acute inflammation and its resolution, including his discovery and characterization of a novel class of anti-inflammatory lipid mediators that have since been named “resolvins.”

Clish received his B.Sc. in chemistry and biological sciences from McGill University in 1991 and his Ph.D. environmental science and chemistry from Portland State University in 1996.

Livia Eberlin
Baylor College of Medicine, USA

Livia Schiavinato Eberlin, PhD received her BS in Chemistry from the State University of Campinas(Sao Paulo, Brazil) and her PhD in Analytical Chemistry from Purdue University. She pursued herpostdoctoral research in Chemistry at Stanford University. Eberlin started her independent career inthe Department of Chemistry at The University of Texas at Austin and then moved to Baylor College of Medicine where she is currently a Professor and Vice-Chair for Research in the Department of Surgery. Dr. Eberlin and her team are recognized for their innovative research in analytical chemistry,medical mass spectrometry, and cancer research. Eberlin is the recipient of many honors for their research, including a NIH K99/R00 Pathway to Independence Award, Forbes 30 under 30 listing in the Healthcare category, a MacArthur Fellowship, and the Norman Hackerman Award. Dr. Eberlin’sresearch program centers around the development and application of novel mass spectrometry technologies in health-related research, with a particular focus on disease detection and diagnosis.

Peter J. Meikle
Baker Heart and Diabetes Institute, Australia

Professor Peter Meikle is Head of the Systems Biology Domain, Co-Lead of the Obesity and Metabolic Diseases Program and Head of the Metabolomics Laboratory at the Baker Heart and Diabetes Institute. He is a Director of the Australian Cardiovascular Alliance and in 2022 was appointed as the inaugural Head of the Baker Department of Cardiovascular Research, Translation and Implementation at La Trobe University. His research focuses on the dysregulation of lipidmetabolism associated with metabolic diseases including obesity, diabetes, cardiovascular andAlzheimer’s disease, and its relationship to the pathogenesis of these disease states.  This work is leading to new approaches to early diagnosis and risk assessment, and to the development of new lipid modulating therapies for chronic disease.

Steffen Neumann
Leibniz Institute of Plant Biochemistry, Germany

Steffen Neuman was trained as a computer scientist in natural sciences at Bielefeld University (Germany), where he also obtained a PhD in computer science. Since 2005 he has led the bioinformatics and mass spectrometry group at the Leibniz Institute of Plant Biochemistry (IPB).

His group focuses on the development of tools and databases for metabolomics and computational mass spectrometry. These include algorithms for data processing of metabolite profiling experiments,which are available in several Open-Source Bioconductor packages. The group also tackles one of the most pressing bottlenecks in Metabolomics, the identification of unknowns in mass spectrometry data.

IPB is member of the MassBank consortium and operated the first MassBank server in Europe. MetFrag was one of the first Open Source in-silico tools for the identification of compounds where no reference spectra are available.

To compare such identification methods on common challenge data, Steffen Neumann initiated the CASMI contest in 2012 together with Emma Schymanski. His team recently evolved into the Computational Plant Biochemistry group, which reflects that there are still plenty of (computational) challenges to be solved to understand how plants work.